A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib, randomized, blinded, placebo-controlled, multiple-ascending dose study in
patients with seasonal or perennial allergic rhinitis to investigate the safety,
tolerability, and pharmacokinetics (PK) of MEMP1972A.